The TAC regimen improved DFS in patients with high-risk HER2-negative breast cancer compared with the TC regimen (TAC vs. TC, 4-year invasive disease-free survival (IDFS) rate, 90.7% vs. 88.2% p=0.04) 7. Here, ERBB2 is linked to breast cancer.